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The exact worldwide incidence of Burkitt’s lymphoma is not known. There are three distinct clinical variants of Burkitt’s
lymphoma, each manifesting differences in epidemiology, clinical presentation, morphology, biology and genetic features:
the endemic (African), the sporadic (non-endemic), and the immunodeficiency-associated form. In particular, we reported
data regarding Burkitt’s lymphoma incidence in the world and across different European countries. Finally, we described
clinic-pathological data of 48 Burkitt’s lymphomas occurred in Italy from 2003 to 2013, in 4 different hospitals, two of which
located in east side, and the other ones located in the west-coast. Forty Burkitt’s lymphomas occurs in children (age range
3–12), and 8 were adulthood Burkitt’s lymphomas (age range 18–87). In the pediatric group the Male:Female ratio (M:F)
was of 4:1, whereas the group of the adult patients has a M:F of 1:1.67. Immunohistochemical detection of Latent
Membrane Protein 1 (LMP1) expression and Epstein-Barr virus Encoded RNA (EBER) In Situ Hybridization (ISH) procedures
have been performed. Lymphocyte B monoclonal spread has been demonstrated using a Polymerase Chain Reaction (PCR)
based method to amplify Fragment Restriction FR1, FR2 and FR3 immunoglobulin heavy chains DNA fragments. Only 38
cases out of 48 were analyzed for LMP-1 showing various percentage of stained cells in 47.4% of the patients.
Considering ISH for EBER detection results:
– 1 out 2 (50%) adult analyzed cases was positive, with 50% of stained tumor cells (this patient was a 22 years old
female, coming from Napoli);
– 15 out 24 (62.5%) children analyzed Burkitt’s lymphomas resulted as positive for EBER;
– the overall positivity has been observed in 16/26 Burkitt’s lymphomas (61.53%).
– Finally, EBV has been detected in children and adult patients, one of them with deregulation of the oncogene c-MYC
by chromosomal translocation.
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EBV, Burkitt’s Lymphoma and tumorigenesis
Epstein Barr virus (EBV) or Human Herpesvirus 4 is an
important example of a transforming virus belonging to
the genus Lymphocryptoviridae, the gamma 1 subtype of
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reproduction in any medium, provided the ormost common viruses in humans. It is able to infect
more than 95% of all individuals within the first four
decades of life.
EBV is usually acquired in early childhood in develop-
ing countries, with no specific characteristics other than
the general symptoms of acute viraemia. However, in de-
veloped countries the infection is usually delayed until ado-
lescence or early adulthood years where it is associated
with the clinical syndrome referred as infectious mono-
nucleosis. Following primary infection, EBV persists lifelong
in the host, selectively infecting in a latent state memory Bal Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited.
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the transformation and persistence of infected B cells are
LMP1 and LMP2a. Through self-aggregation on the sur-
face of the infected B cell, LMP1 and LMP2a provide ac-
tive signals leading to the proliferation of transformed
memory B cells that remain in the host for life [1]. LMP1
and other EBV proteins such as Epstein Barr Nuclear
Antigen 2 (EBNA2), are highly antigenic, marking the in-
fected B cells for destruction by cytotoxic T cells (CTLs)
in the healthy individual. On the other hand, in immuno-
depressed patients as well as in transplant recipients
undergoing immunosuppression, CTLs are immobilized,
allowing for the proliferation and immortalization of in-
fected B cells [1]. EBV has been demonstrated to be in-
volved in the development of numerous malignancies,
both in immunocompetent hosts and in immunocom-
promised individuals [2]. The first association was with
the endemic Burkitt’s lymphoma. The EBV genome is de-
tected in the majority of neoplastic cells in all patients af-
fected by endemic Burkitt’s lymphoma [3,4] and there is
strong epidemiological association with endemic malaria
[5], although there has never been a conclusive population
study in support of a direct role of malaria in causation of
Burkitt’s lymphoma.
EBV may be detected also in approximately 30% of
sporadic Burkitt’s lymphoma cases and it is identified in
25-40% of immunodeficiency-associated Burkitt’s lymph-
omas [6].
A setting of profound immunosuppression, as in the ter-
minal phases of Human Immunodeficiency Virus (HIV)
infection or in organ transplant recipients, leads to loss of
control of EBV infection, allowing deregulated prolifera-
tion of EBV infected lymphocytes. In this case a spectrum
of EBV-driven lymph proliferation, ranging from hyper-
plasia to frank Non Hodgkin Lymphoma (NHL) could de-
rive [7]. We have to remember that the majority of EBV
infections that occur after transplantation, especially in
adults, are clinically silent reactivations. This leads to a
subsequent delay in the diagnosis of lymph proliferative
disorders. Studies have shown a positive correlation be-
tween the level of EBV DNAemia after transplantation
and the development of post-transplant lymph prolifera-
tive disorders (PTLD) which has significant implications
in order to monitor and quantify EBV-DNA load after
transplantation as a prognostic marker for the develop-
ment of PTLD [8-10]. Other lymphomas (subtypes of both
Hodgkin’s and non-Hodgkin’s lymphomas) are also known
to be associated with EBV infection. Epithelial malignan-
cies such as lymphoepitheliomas of nasopharynx [11] and
gastric carcinoma [12] are currently included in the list of
EBV associated tumours.
In a recent review, Thorley-Lawson et al. [13] described
the relationship between EBV infection and Burkitt’s
lymphoma. The tumour cells were found to express EBNAin their nuclei, a serologically defined, putative tumour
antigen, composed of six components, of which only one,
EBNA-1, was expressed in EBV-positive Burkitt’s lymph-
omas [14]. One observation that favored the carcino-
genic role of EBV in Burkitt’s lymphoma was the
finding that EBV was an extremely potent transform-
ing virus in culture for the same cell type that develops
into Burkitt’s lymphoma, the B lymphocyte [14], being
able to convert >50% of B cell into continuously prolifer-
ating, latently infected lymphoblastoid cell lines (LCLs)
within a few days.
The link between EBV and human cancer is constantly
evolving and it lies in the molecular events occurring in
Burkitt’s lymphoma pathogenesis.
EBV can display three patterns of latent gene expression:
latency I (latency programme), II (default programme)
and III (growth programme). Latency III is characterized
by expression of all the latent genes (EBNAs, LMPs and
EBERs) and occurs on primary infection of B cells. In con-
trast, persistent infection in vivo is characterized by ex-
pression of EBNA-1 and LMP-2 plus the EBERs [15]. In
latently infected LCLs, EBV expresses the full spectrum of
latent genes; two small nuclear RNAs (EBERs), the highly
spliced BamHI rightward transcripts (BARTs), three inte-
gral latent membrane proteins, (LMP1, −2A and -2B) and
six EBV nuclear antigens (EBNA1, −2, −3A, −3B, −3C,
and EBNA-LP) [16].
While EBNA-1 and the EBERs (latency I) have been
generally thought to be the only EBV genes expressed in
endemic Burkitt’s lymphoma, with a specific role in pre-
vention of apoptosis and survival of neoplastic cells,
other recent studies have found that a minor proportion
of these tumours has a novel form of latency with a dif-
ferent and broader gene expression profile than previ-
ously thought in which the EBNA-3A, 3B, 3C and LP
latent genes are expressed in the absence of EBNA-2
and LMP-1 or 2 [17]. Subsequentely, further investiga-
tion has demonstrated that endemic Burkitt’s lymph-
omas may be constituted of tumour cells expressing
variable patterns of EBV gene expression, each of which
confer a different level of resistance to apoptosis [17].
Thus, EBNA-1, 3A, 3B, 3C and LP positive and EBNA-2,
LMP negative Burkitt’s lymphoma cells were the most
resistant to apoptosis, while EBNA-2 positive, LMP1-
negative Burkitt’s lymphoma cells displayed reduced but
“intermediate” resistance [18,19].
Other studies suggested that biopsies performed on
Burkitt’s lymphomas mass can express additional latent
proteins, including LMP1, LMP2A and EBNA2 [3]. In
particular, LMP2A increases the levels of prosurvival B
Cell Lymphoma (Bcl) family members in B lymphocytes,
allowing for bypass of p53 inactivation in a MYC tumor
model. Recently, some Authors have proposed a role for
LMP2A early in development of Burkitt’s lymphoma,
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that contain a MYC translocation. The expanded cells
increase the probability of acquiring a p53 mutation,
leading to tumor progression. After the p53 mutation,
the tumor cells become less dependent on LMP2A and
immune selection may explain the low levels of LMP2A
present in tumor biopsies [20].
Burkitt’s lymphoma
Burkitt’s lymphoma is a highly aggressive B cell NHL
with an extremely short doubling time that often presents
in extra nodal sites or as an acute leukemia. No single para-
meter (such as morphology, genetic analysis or immuno-
phenotyping) can be used as the gold standard for the
diagnosis of Burkitt’s lymphoma, but a combination of
several diagnostic techniques is necessary.
Epidemiology
The exact worldwide incidence of Burkitt’s lymphoma is
not known, as collection of these types of epidemiologic
data is limited by a lack of resources that are needed for
case ascertainment and accurate diagnosis in the devel-
oping countries that have the highest apparent incidence
(eg, equatorial Africa) [21].
There are three distinct clinical variants of Burkitt’s
lymphoma, each manifesting differences in epidemiology,
clinical presentation, morphology, biology and genetic fea-
tures: the endemic (African), the sporadic (non-endemic),
and the immunodeficiency-associated form. The endemic
and sporadic clinical variants of Burkitt’s lymphoma differ
geographically.
a. Endemic Burkitt’s lymphoma occurring in
Equatorial Africa, Papua New Guinea, represents the
most common childhood malignancy of these areas,
and shows geographic occurrence corresponding to
the geographical distribution of endemic malaria
[22]. Burkitt’s lymphoma accounts for 30 to 50
percent of all childhood cancer in equatorial Africa
with an estimated incidence of 3 to 6 cases per
100,000 children per year [21]. The peak incidence
occurs in children age four to seven years, and the
male:female ratio is approximately 2:1.
b. Sporadic Burkitt’s lymphoma occurring in the US
and Western Europe children and young adults.
This variant accounts for 30-50% of all childhood
lymphomas and less than 1 percent of adult NHLs
in the US [23], with an estimated incidence of
approximately three cases per million persons per
year in both children and adults. In Europe, the
incidence is approximately 2.2 cases per million
persons per year [24]. The peak incidence occurs
in children age 11 years. Among adults, sporadic
Burkitt’s lymphoma is typically seen in patientsless than 35 years of age, with a median age
at diagnosis of 30 years [25]. The majority of
patients are males with a 3 or 4:1 male:female
ratio [22,26,27].
c. Immunodeficiency-associated Burkitt’s
lymphoma occurring in association with the HIV
infection, and less commonly in patients with other
causes of immunodeficiency (e.g., recipients of organ
transplants). In HIV + patients, Burkitt’s lymphoma
typically occurs as the initial manifestation of the
acquired immunodeficiency syndrome and affects
those still immune competent patients with a
relatively high CD4 count (e.g., >200 cells/microL)
and no opportunistic infections [28], in this way
suggesting that HIV itself may have an oncogenic
role [29]. In comparison to the majority of other
HIV-associated lymphomas, the rate of Burkitt’s
lymphoma in the HIV-positive population has not
decreased with the advent of Highly Active Anti-viral
Therapy (HAART).
The geographic distribution of Burkitt’s lymphoma
identifies high, intermediate and low-risk areas [30]. The
area of highest risk for Burkitt’s lymphoma appears to be
between 10° north and 10° south of the equator and in
Papua New Guinea. The zone of intermediate risk for
Burkitt’s lymphoma encompasses Southern Europe (Spain,
France and Portugal), North Africa, and Asia as far west
as Iraq and Kuwait Countries in this zone include also
Denmark and the Netherlands since both have slightly ele-
vated Age Standardized Rates compared with the general
pattern in Northern and Eastern Europe. The zone of
low risk includes most of the remainder of Northern and
Eastern Europe, and North and parts of South America
and East Asia. In these areas Burkitt’s lymphoma accounts
for 6-15% of lymphomas.
Etiology
Burkitt’s lymphoma was first described in 1958 by a British
surgeon working in Uganda who noted a unique, rapidly
growing jaw malignancy in children, that was especially
common in low altitude, high rainfall areas with a mean
temperature over 16 Celsius degrees [31]. The distribution
corresponded with that of holoendemic malaria [32], im-
plicating malaria in the aetiology. In 1964, the EBV was
identified in cultured cell-lines of the tumour [33], and its
consistent presence in African Burkitt’s lymphoma impli-
cated a virus in the aetiology of a human cancer for the
first time [34]. The EBV is found in up to 95% of Burkitt’s
lymphoma tumours from high-risk areas [35], but in fewer
than 30% from low-risk countries [36]. Areas of inter-
mediate risk have intermediate proportions of EBV posi-
tive (EBV+) tumours [37]. However, recent works suggest
that a low socio-economic status and an early EBV
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EBV + Burkitt’s lymphoma in low-incidence areas. In
immunodeficiency-associated cases EBV is identified in
only 25-40% of the cases. However epidemiological studies
suggest that malaria and EBV or HIV alone cannot ac-
count for the distribution of endemic Burkitt’s lymphoma
in high risk countries. Clustering in time and space, and
within same families has been observed, particularly
in areas of high incidence, but so far these studies have
failed to firmly implicate either genetic or environmental
factors. Finally, arboviruses and plant tumour promoters
are other possible local cofactors.
Genetics
Different and multiple environmental exposure may
converge in a common pathogenetic mechanism involv-
ing the MYC gene at chromosome 8q24. In fact, all tu-
mours contain the same chromosomal translocations,
which culminate in the deregulation of the oncogene
c-MYC. The translocations involve the MYC location
(8q24) and one of the immunoglobulin loci on chromo-
somes 2, 14, or 22 [38,39]. Most of the cases of Burkitt’s
lymphomas presented the MYC translocation at band
8q24 to the Immunoglobuline heavy chain locus (IGH)
(14q32) or, less commonly, at the lambda (22q11) or
kappa (2p12) light chain loci (IGL). The reciprocal trans-
location t(8:14) occurs in approximately 80% of tumours
[40], the remaining 20% being represented by t(2;8) and
t(8;22). In African endemic cases, the breakpoint on
chromosome 14 involves the heavy-chain joining region
and originate from aberrant somatic hypermutation,
whereas in sporadic forms, the translocation involves the
heavy chain switch region [41]. Finally, up to 10% of the
cases may lack a demonstrable MYC translocation by
Fluorescence In Situ Hybridation (FISH), otherwise evi-
denced using other molecular techniques. Translocation
and deregulation involving MYC gene on chromosome 8
is highly characteristic but not specific for Burkitt’s
lymphoma. Other genetic and epigenetic alterations can
occur in a subgroup of Burkitt’s lymphoma, involving for
example TP53 in immune-competent and immune-
deficient patients, HIV positive individuals and transplants
recipients [42]. In a recent work the first completely
sequenced genome from a Burkitt’s lymphoma tumor
and germ line DNA from the same affected individual
has been described [43]. Authors further sequenced
the exomes of 59 Burkitt’s lymphoma tumors, comparing
them to sequenced exomes from 94 Diffuse Large B Cell
Lymphomas (DLBCLs). 70 genes that were recurrently
mutated in Burkitt’s lymphomas, including Inhibitor
of DNA binding 3 (ID3), Guanine Nucleotide-binding
Protein Alpha 13 (GNA13), Rearranged during Transfec-
tion oncogene (RET), Phosphatidyl Inositol 3-Kinase
Regulatory Subunit 1 (Pi3KR1) and the Switch/SucroseNon Fermentable (SWI/SNF) genes, AT Rich Interactive
Domain 1A (ARID1A) and SWI/SNF-related Matrix-
Associated Actin-Depended Regulator of Chromatin sub-
family A-member 4 (SMARCA4) have been identified. In
particular ID3 mutations occurred in 34% of Burkitt’s
lymphomas and not in DLBCLs.
Histopathology
Despite chromosomal differences, the “endemic” and
“sporadic” forms are indistinguishable morphologically
and cytologically [44]. The classical prototype of Burkitt’s
lymphoma is observed in endemic form and in a high
percentage of sporadic cases, particularly in children,
but in only a minority of sporadic and immunodefi-
ciency associated adult cases. Neoplastic cells are uni-
form and small-medium sized with round nuclei, similar
or smaller to those of histiocytes, and several or multiple
small basophilic paracentrally situated nucleoli. Cytoplasm
is deeply basophilic, moderately abundant; it can show
slight retraction after formalin fixation and contains lipid
vacuoles. Neoplastic cells show a diffuse monotonous
pattern of growth, a high mitotic count as well as high
apoptotic fraction. Characteristically, there are numerous
admixed tingible body macrophages, phagocytosing abun-
dant apoptotic debris and creating a starry-sky pattern.
Some cases, characterized by a limited stage disease and a
good prognosis, may also have a florid granulomatous re-
action, causing diagnostic problems in the recognition of
the tumour. There are cases in which tumor cells exhibit
eccentric nucleus with a single central nucleolus: these
cases are referred as Burkitt’s lymphoma with plasmacy-
toid differentiation and can be observed more commonly
in immunodeficient patient. Other cases, in the past de-
fined as atypical Burkitt’s lymphoma/Burkitt like lymph-
oma, may show greater nuclear pleomorphism with more
prominent nucleoli, but fewer in number. Atypical Bur-
kitt’s lymphomas occur more frequently in many cases of
sporadic adult forms.
Immunophenotype
Burkitt’s lymphoma, regardless of subtype typically ex-
presses monotypic surface IgM with light chain restric-
tion, pan-B-cell antigens, including the CD19, CD20,
CD22 and CD79a and co-expresses CD10, CD38, CD43,
CD77, Bcl6, and p53, but not CD5, CD23, Bcl2 (or only
weakly positive in almost 20% of cases, generally adult
patients), CD138 or TdT, thus suggesting follicle centre
origin. Burkitt’s lymphoma with plasmacytoid differenti-
ation has in addition monotypic cytoplasmic Ig. The pro-
liferation index is near to 100%.
Clinical features and prognosis
Staging is performed using the Ann Arbor or, more often,
the St Jude/Murphy staging system [45]. Approximately
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while 70% present with widespread disease (stage III or
IV). Patients often present with bulky disease, a high
tumour burden due to its short doubling time, and with a
high risk for spread to the central nervous system (CNS)
and bone marrow. A minority of patients with Burkitt’s
lymphoma presents with leukemic disease, previously
classified as ALL (acute lymphocytic leukaemia), L3 type.
In endemic Burkitt’s lymphomas, the jaws and other facial
bones are the most frequent sites of clinical presentation.
The distal ileum, coecum, omentum, gonads, kidneys,
long bones, thyroid, salivary glands and breast may also be
affected. In sporadic Burkitt’s lymphomas, jaw tumours
are rare, while the majority of case are represented by
intra-abdominal masses. In immunodeficiency associated
forms, nodal localization is frequent as well as bone
marrow involvement. Sporadic and immunodeficiency-
associated Burkitt’s lymphomas do not share endemic
Burkitt’s lymphomas exquisite sensitivity to chemother-
apy, therefore historically the prognosis had been poor,
particularly among adults. Although the most important
prognostic features have yet to be determined, some clin-
ical factors associated with worse outcome in adults and
children include older age, advanced stage, poor perform-
ance status, bulky disease, high Lactate Dehydrogenase
(LDH), and CNS or marrow involvement, unresectable
tumour >10 cm in diameter. Among paediatric patients, a
poorer prognosis is associated with age over 15 years [46].
A good prognosis is associated with resectable abdom-
inal disease [44]. High-intensity chemotherapy, some-
times combined with CNS prophylaxis, yields excellent
survival in children, both with localized disease and with
widespread disease [47]. When similar aggressive chemo-
therapeutic regimens have been administered to adults,
good outcomes have been achieved, with overall survival
(OS) rates of 50%–70% [48].
WHO 2008 Classification: a new entity
The WHO provides an overlap category termed “B
cell lymphoma, unclassifiable, with features intermedi-
ate between diffuse large B cell lymphoma and Burkitt
lymphoma”.
These neoplasms are very aggressive lymphomas that share
morphological and genetic features of DLBCL and Burkitt’s
lymphoma, but for biological and clinical reasons should be
not included in one of the two categories. Morphologically
these lymphomas are typically composed of a diffuse pro-
liferation of medium-large sized cells with few admixed
small lymphocytes and no stromal fibrosis. A starry-sky
pattern, as well as many mitotic figures and apoptotic
bodies can be observed, resembling Burkitt’s lymphoma.
There is a marked cellular pleomorphism: in some
cases, cells resemble those of Burkitt’s lymphoma but with
more variation in nuclear size and cellular contour; othercases are morphologically similar to Burkitt’s lymphoma,
but with an atypical immunophenotype or genetic fea-
tures; other cases share the same immunophenotype of
Burkitt’s lymphoma but have an intermediate morphology
between Burkitt’s lymphoma an DLBCL; in rare cases, de-
fined ‘blastic or blastoid’, the nuclei are very small, resem-
bling lymphoblastic lymphoma.
The diagnosis of this unclassifiable type of lymphomas
should not be made in:
– cases of morphologically typical DLBCL with MYC
rearrangement;
– typical Burkitt’s lymphomas in which a MYC
rearrangement cannot be demonstrated;
– atypical Burkitt’s lymphomas with a demonstrable
IG-MYC rearrangement.
Cases that morphologically resemble Burkitt’s lymph-
oma and or DLBCL may be placed in this category when:
– the immunophenotype is suggestive of Burkitt’s
lymphoma (CD10+, Bcl6+, Bcl2-);
– Bcl2 is moderately-strongly positive (double-hit
lymphoma with bot MYC an BCL2 translocations);
– Ki67 labelling expression is heterogeneous (50-100%);
– TdT is positive
These intermediate lymphomas express B-cell markers
and surface Ig, that in so called double-hit cases can
stain negative.
Approximately 35-50% of the cases have 8q24/MYC
translocations. Many cases have non IG-MYC transloca-
tions, approximately 15% having a BCL2 translocation,
sometimes also together MYC translocations (double-hit
lymphomas). Less frequently, BCL6 translocation have
been observed together MYC and/or BCL2. These type
of double/triple hit lymphomas reflect a complex karyo-
type and are more common in elderly patients [25].
Differential diagnosis
The main diagnostic problem is to differentiate Burkitt’s
lymphoma from other types of high-grade B-cell lymph-
oma, especially from diffuse large B-cell lymphoma. This
problem is most evident for adults because a much
lower proportion of NHLs in adults is Burkitt’s lymphoma
if compared with children population, and because adults
(more than children) often have the atypical Burkitt’s
lymphoma variant, with morphologic features resembling
those of diffuse large B-cell lymphoma.
The immunophenotypic prototype of Burkitt’s lymph-
oma is IgM+/CD10+/bcl-2–/bcl-6+ with the Ki-67 prolif-
eration index (PI) nearly at 100%; however, cases with an
aberrant immunophenotype (such as bcl-2 expression)
exist [49]. Occasional diffuse large B-cell lymphomas may
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showing slight nuclear pleomorphism, with or without a
starry-sky pattern (DLBCL-HPSS). Furthermore, some
DLBCLs may share immunophenotypic features of Burkitt’s
lymphoma [50]. Furthermore, c-MYC rearrangement is
not unique in Burkitt’s lymphoma and may occur in
DLBCLs [49]. These gray-zone cases is an important
diagnostic challenge, because the distinction is of great
clinical significance for the different treatment strategies
for Burkitt’s lymphoma and DLBCL [45]. Generally, we
can consider the following key-points to make a correct
differential diagnosis.
Features that favour Burkitt’s lymphoma include morph-
ology, an immunophenotype that is CD20+, CD10+, Bcl-6+,
Bcl-2−, TdT−, and monotypic sIg+, with virtually all cells
Ki67+ (proliferation), and a translocation involving c-Myc
and IgH or IgL, without rearrangements involving the bcl-
2 or bcl-6 genes [49]. Features that rule out the diagnosis
of Burkitt’s lymphoma include BCL6 gene rearrangement,
independent from bcl-6 nuclear staining, bcl-2 positivity,
presence of t(14;18) and a ki67 staining less than 95%.
c-MYC protein expression has been suggested to favour
Burkitt’s lymphoma over DLBCL, but rare cases of
Burkitt’s lymphoma can be c-MYC protein negative
and some large B-cell lymphomas also express c-MYC
protein (5%–15% of them having a MYC rearrange-
ment) [51].
Studies of micro RNA (miRNA) profiling have evidenced
the molecular differences existing between Burkitt’s lymph-
oma and DLBCL and have demonstrated that the three
Burkitt’s lymphoma variants are representatives of the
same biological entity with only marginal miRNA expres-
sion differences between endemic and sporadic form [52].
In particular, a signature of 38 miRNAs containing
MYC and nuclear factor-κB (NF-κB) pathway-associated
miRNAs has been obtained, differentiating Burkitt’s
lymphoma from DLBCL.
Other type of lymphoproliferative diseases (follicular
lymphoma, mantle-cell lymphoma, and plasma-cell mye-
loma) infrequently share MYC translocations. In lymph-
omas other than Burkitt type, c-myc is more likely to
have variant translocations (with IgL or other non-Ig
partners, rather than IgH), and neoplastic cells tend to
have more complex karyotypic abnormalities.
Other entities taking part in the differential diagnosis of
Burkitt’s lymphoma include T lymphoblastic lymphoma/
leukemia (expressing T cell markers and TdT) and blas-
toid mantle cell lymphoma (CD5 and cyclin D1 positive).
The florid follicular hyperplasia, with highly active fol-
licle centers with many blast cells and tingible body
macrophages, overlaps with the starry-sky appearance
and with the immunophenotype of Burkitt’s lymphoma.
Demonstration of monotypic surface immunoglobulin
can definitively exclude a reactive process.Clinic-pathological data of Burkitt’s lymphoma
cases occurred in Italy from 2003 to 2013. A
representative four hospitals based survey
Patient cohort characteristics
Upon approval by the Ethical Committees of the partici-
pants institutions, anatomic pathologists and physicians
from four Italian hospitals were asked to furnish data re-
garding Burkitt’s lymphomas occurred in Italy in the last
ten years (2003–20013). Two hospitals were located in east
Italy: University Hospital of Foggia and General Hospital
of Ascoli Piceno. The other hospitals are located in the
west-coast of Italy: General Hospital - AORN Ospedale dei
Colli ‘Vincenzo Monaldi’, Napoli) and Children University
Hospital - Ospedale Santobono Pausillipon, Napoli. A total
of 48 cases of Burkitt’s lymphomas has been recorded. Pa-
tients came from Foggia, Napoli and Ascoli Piceno and
their broad provinces.
The study population consisted of 40 children and 8
adults. In children group there were 32 boys and 8 girls
with a male to female ratio of 4:1; in the adult popula-
tion there were 3 males and 5 females with a M:F of
1:1,65. Concerning the primary clinical presentation, our
Burkitt’s lymphomas of the adults occur as a node mass
in 3 cases and as abdominal mass as well as iliac and
appendiceal mass in one case respectively. Abdominal
mass is the most common manifestation of Burkitt’s
lymphoma of the child in our study, this presentation
occurring overall in 12 patients (30%). In eight children
(20%) it arises as superficial nodes mass in 4 cases (10%
of all lymphomas) involving cervical nodes, in 2 as in-
guinal nodes mass and in 2 as axillary node mass (coin-
ciding with 5% of all lymphomas). In 2 patients the
disease arises with tonsils involvement and in other 2
cases with pleural effusion. Furthermore, the primary
presentation with liver, retroperitoneum, mesocolon
nodes, small bowel involvement and as a pelvic or mes-
enteric mass regards individuals patients (each case rep-
resents the 2,5% of all lymphomas). Staging is performed
using the St Jude/Murphy staging system [45]. All pa-
tients and/or their relatives gave their informed written
consent.
Materials and methods
The specimens from all cases were fixed in 10% forma-
lin, processed by routine methods, and embedded in
paraffin. The final diagnosis of Burkitt’s lymphoma, ob-
tained comparing morphological features with immuno-
histochemical results for a panel of antibodies including
CD3, CD5, CD20, CD10, CD79a, bcl-2, bcl-6 and Ki-67
(MIB-1), was carefully reviewed at the Section of Path-
ology of the University of Foggia by two pathologists
(GP and RZ) and showed in Table 1.
Immunohistochemical detection of LMP1 Expression
and EBER In Situ Hybridization Procedures have been
Table 1 Clinico-pathological features of Italian study population and results regarding immunohistochemical findings
Case Italian City (Region) Year Age Sex Site Immunohistochemistry (IHC)
CD20 CD79a CD10 CD3 CD5 Bcl-6 Bcl-2 Ki67 LMP1
Case 1 Foggia (Puglia) 2012 8 M Tonsil P P P N n.d. P N >90 N
Case 2 Foggia (Puglia) 2012 52 F Node P P P N N P N >95 N
Case 3 Foggia (Puglia) 2006 38 M Abdominal mass P P n.d. N n.d. n.d. n.d. n.d. n.d.
Case 4 Ascoli Piceno (Marche) 2005 41 F Node P n.d. N N n.d. P N 100 N
Case 5 Ascoli Piceno (Marche) 2006 18 F Node P n.d. P N n.d. P P 100 N
Case 6 Ascoli Piceno (Marche) 2011 87 M Ileum P n.d. N N n.d. P n.d. 98 P
Case 7 Ascoli Piceno (Marche) 2012 37 M Appendix P P n.d. N n.d. P N 100 n.d.
Case 8 Naples* (Campania) 2003 CHILD M Retroperitoneum P P n.d. N n.d. n.d. n.d. >95 P
Case 9 Naples* (Campania) 2003 CHILD M Abdominal mass P P n.d. N n.d. n.d. n.d >95 P
Case 10 Naples* (Campania) 2003 CHILD M Small bowel P P n.d. N n.d. n.d. n.d. >95 P
Case 11 Naples* (Campania) 2003 CHILD M Ileum P P n.d. N n.d. n.d. n.d. >95 n.d.
Case 12 Naples* (Campania) 2003 CHILD F Mesocolon nodes P n.d. n.d. N n.d. n.d. N >95 P
Case 13 Naples* (Campania) 2004 4 M Abdominal mass P P P N n.d P N >90 P
Case 14 Naples* (Campania) 2004 5 M Cervical nodes . P P P N n.d n.d n.d >95 n.d.
Case 15 Naples* (Campania) 2004 CHILD M Axillary nodes P P n.d N n.d n.d n.d >95 n.d.
Case 16 Naples* (Campania) 2004 CHILD F Nasopharinx P P n.d N n.d n.d n.d >95 P
Case 17 Naples* (Campania) 2005 6 M Abdominal mass P P P N n.d P N >95 P
Case 18 Naples* (Campania) 2005 6 M Inguinal nodes P P P N n.d P N >95 n.d.
Case 19 Naples* (Campania) 2005 4 F Pelvic mass P P P N n.d P N >95 P
Case 20 Naples* (Campania) 2005 3 F Ileum P P P N n.d P N >95 N
Case 21 Naples* (Campania) 2005 11 M Axillay nodes P P P N n.d P N 100 N
Case 22 Naples* (Campania) 2005 4 F Ileum P P P N n.d P N 90 P
Case 23 Naples* (Campania) 2005 12 M Abdominal mass P P P N n.d P N >95 N
Case 24 Naples* (Campania) 2006 5 M Inguinal nodes P P P N n.d P N 100 P
Case 25 Naples* (Campania) 2006 8 M Abdominal mass P n.d P N n.d P N >90 P
Case 26 Naples* (Campania) 2006 12 F Ileum P P P N n.d P Focal P 90 N
Case 27 Naples* (Campania) 2006 7 M Mesenteric mass P P P N n.d P N >95 P
Case 28 Naples* (Campania) 2006 8 M Liver P n.d P N n.d P N 100 P
Case 29 Naples* (Campania) 2007 6 F Abdominal mass P n.d n.d N n.d n.d N 100 n.d.
Case 30 Naples* (Campania) 2007 7 M nasopharynx P n.d P N n.d. P N >95 N
Case 31 Naples* (Campania) 2007 7 M Tonsil P n.d P N n.d. P N >95 n.d.
Case 32 Naples* (Campania) 2007 4 M Abdominal mass P P P N n.d. P N 95 P
Case 33 Naples* (Campania) 2007 6 M Cervical nodes P P P N n.d. P N 95 N
Case 34 Naples* (Campania) 2008 10 M Abdominal mass P P P N n.d. P N >90 P
Case 35 Naples* (Campania) 2008 7 M Nasopharynx P P P N n.d. P N 100 N
Case 36 Naples* (Campania) 2008 6 M Cervical nodes P P P N n.d. P N >95 P
Case 37 Naples* (Campania) 2008 11 M Cervical nodes P P P N n.d. P N 100 N
Case 38 Naples* (Campania) 2008 10 M Abdominal mass P P P N N P N >95 N
Case 39 Naples* (Campania) 2009 3 M Abdominal mass P P P N N P N >90 N
Case 40 Naples* (Campania) 2010 11 M Abdominal mass P P P N N P N >95 N
Case 41 Naples* (Campania) 2010 11 M Abdominal mass P P P N n.d. P N 100 N
Case 42 Naples* (Campania) 2010 5 F Nasopharynx P n.d. P N n.d. P N 100 N
Case 43 Naples* (Campania) 2011 6 M Ileum P P P N N P N 95 P
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Table 1 Clinico-pathological features of Italian study population and results regarding immunohistochemical findings
(Continued)
Case 44 Naples* (Campania) 2012 9 M Ileum P P P N N P N >90 N
Case 45 Naples* (Campania) 2012 6 M Pleural effusion P P P N n.d. P faint N >90 N
Case 46 Naples* (Campania) 2013 3 M Pleural effusion P P P N n.d. P N 100 N
Case 47 Naples° (Campania) 2003 67 F n.d. P P n.d. N n.d. n.d. n.d. n.d. n.d.
Case 48 Naples° (Campania) 2003 22 F n.d. P P P N N n.d. n.d. n.d. n.d.
Legend. *, Ospedale Santobono Pausillipon; °, AORN Ospedale dei Colli -‘Vincenzo Monaldi’; P, positive; N, negative; n.d., not determined.
Figure 1 Burkitt’s lymphoma of the child - Histopathology and
immunohistochemistry. a, Medium sized lymphocytes with high
mitotic index and macrophages with tingible bodies (Hematoxylin-Eosin,
60x); b, CD79a expression; c, bcl6 expression; d, CD 20 expression;
e, CD 10 expression; f, Ki 67 expression (LSAB-HRP, nuclear
counterstaining with type II Gill’s Haematoxylin).
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guidelines [53].
In our study In Situ Hybridization (ISH) has been per-
formed using Ventana® EBER ISH iView Blue Plus
Kit. It is performed using a cocktail of EBV encoded
small RNA probes. The intended target is the early
RNA transcripts of EBV accumulated in the nucleus
of EBV-infected cells as evaluated by a blue reaction
that is localized to EBV-infected nuclei.
In our study, Lymphocyte B monoclonal spread has
been demonstrated using a PCR based method to amp-
lify FR1, FR2, and FR3 immunoglobulins heavy chains
DNA fragments according to manufacturer instructions
(Invitrogen, Carlsbad, CA, USA).
At first time the slides were assessed either positive or
negative for EBV latent infection. The cases assessed as
positive were then examined as regard the percentage
value of stained cells.
Results and discussion
After active infection the EBV resides in a latent form with
B cells providing the main cellular reservoir [54]. Latent in-
fection by EBV can occur in three forms (latency I, latency
II and latency III), each one being marked by a different
viral gene expression profile. In fact, not all stages of EBV
latency express LMP-1 and questions have been raised
about the sensitivity of the immunohistochemistry (IHC)
to detect the virus.
Detection of EBV can be also performed by EBER in-
situ hybridization (ISH). EBER actually consists of two
small EBV latency transcripts of 166 and 172 bases
respectively, called EBER-1 and EBER-2 [55]. These tran-
scripts are non-polyadenlylated and therefore not trans-
lated into proteins, detectable by IHC. They are naturally
amplified and present at high levels in all latency forms
of EBV infection, making them ideal targets for ISH,
which is widely considered the gold standard for the
detection of EBV latent infection in formalin fixed,
paraffin embedded tissue (FFPE), being more sensitive
than the immunohistochemical evaluation of LMP-1
expression [56].
In our study EBV has been detected both in adult pa-
tients (in one of them with deregulation of the oncogenec-MYC by chromosomal translocation) and children by
two different diagnostic tests. Histopathologic, immuno-
histochemical and ISH findings, useful to achieve the
final diagnosis of Burkitt’s lymphoma have been reported
in Table 1 and showed in Figures 1, 2, 3 and 4.
The immunohistochemical detection of LMP-1 was
analyzed in 38 samples (Figure 3).
In the adult population the detection was performed
in 4 cases and just 1 expressed LMP-1 (25%). We have
information about the presence of deregulation of the
oncogene c-MYC by its chromosomal translocation at
band 8q24 to the Ig heavy chain region IgH (14q32) in
two lymphomas; one of them was precisely the adult
Burkitt’s lymphoma positive for LMP-1 (in almost 25%
of neoplastic cell). In particular, this case referred to a
male patient, 37 years old, living in Ascoli Piceno. He is
the only patient without Italian origins, as he comes
from the Republic of Peru.
Figure 2 Burkitt’s lymphoma of the adult - Histopathology and immunohistochemistry. a, Medium sized lymphocytes with high mitotic
index and macrophages with tingible bodies (Hematoxylin-Eosin, 40x); b, CD79a expression; c, bcl6 expression; d, CD 20 expression; e, CD 10
expression; f, Ki- 67 expression (LSAB-HRP, nuclear counterstaining with type II Gill’s Hematoxylin).
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immunodeficient.
In the children subgroup LMP-1 was detected in 34
cases, 17 positively staining for the marker (50%). Over-
all LMP-1 was positive in 18/38 cases (47.4%) and nega-
tive in 20/38 (52.6%). We considered as positive cases
with any percent of stained cells. The percentage of
stained cells ranged from focal to more than 70% of lym-
phomatous cells.Figure 3 Immunohistochemical expression of LMP-1 in Burkitt’s
lymphoma. Note the strong nuclear staining of EBV-infected
cells. (LSAB-HRP, x400; nuclear counterstaining with type II
Gill’s Haematoxylin).Considering ISH for EBER detection results:
– 1 out 2 (50%) adult analyzed cases was positive,
with 50% of stained tumor cells (this patient
was a 22 years old female, coming from
Napoli);Figure 4 In situ hybridization for EBER in Burkitt’s lymphoma.
Note diffuse and strong staining showing early RNA transcripts of
EBV accumulated in the nucleus of EBV-infected cells (Ventana® EBER
ISH iView Blue Plus Kit; original magnification x200).
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lymphomas resulted as positive for EBER;
– the overall positivity has been observed in 16/26
Burkitt’s lymphomas (61.53%).
In children group of Burkitt’s lymphoma, only in 23
cases we have been able to compare IHC results with
ISH findings. As diagnostic test, IHC has shown a sens-
ibility of 28.57%, a specificity of 55.5%, a PPV of 50%, a
NPV of 33.3% and an accuracy of 39.13%. We have ob-
served a positive concordance IHC-ISH in 17.39% of
cases, and a negative one in 21.73%. The total observed
concordance was 39.13%, the expected concordance was
10%. The k coefficient was good (0.32).
Our study has demonstrated that although IHC is a
good prognostic indicator when used in combination
with molecular methods, it is not satisfactory when eval-
uated as detecting test as used alone. Adding ISH for
EBER has the advantage to preserve the morphological
context of signals in FFPE samples and increased the
sensitivity of diagnostic EBV detection.
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